sorafenib has been researched along with Sarcopenia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, Y; Chen, YT; Cheng, TY; Hou, MC; Huang, YH; Lee, PC | 1 |
| Alsebaey, A; Aly, RA; Badran, H; Elsabaawy, MM; Ragab, A; Sabry, A | 1 |
| Enomoto, N; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yasui, Y | 1 |
| Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L | 1 |
| Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB | 1 |
| Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M | 1 |
1 trial(s) available for sorafenib and Sarcopenia
| Article | Year |
|---|---|
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sarcopenia; Sorafenib | 2010 |
5 other study(ies) available for sorafenib and Sarcopenia
| Article | Year |
|---|---|
Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sarcopenia; Sorafenib | 2020 |
Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Prognosis; Radiofrequency Ablation; Sarcopenia; Sorafenib; Survival Rate | 2020 |
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Portal Vein; Prognosis; Proportional Hazards Models; Sarcopenia; Serum Albumin; Sorafenib; Treatment Outcome | 2018 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines | 2015 |
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sarcopenia; Sorafenib; Survival Analysis | 2012 |